MedTrace Logo

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

NCT00972049 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-03-04

No results posted yet for this study

Summary

The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose to Japanese healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

AZD2516

Capsule administered once orally. Specific dose depends on dose panel.

DRUG

Placebo

Capsule administered once orally

Sponsors & Collaborators

Principal Investigators

  • Anders Neijber, MD, PhD · AstraZeneca R&D Södertälje

  • Shunji Matsuki, MD, PhD · Kyusyu Clinical Phramacology Research Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00972049 on ClinicalTrials.gov